We have previously identified compstatin, a 13-residue cyclic peptide, that inhibits complement activation by binding to C3 and preventing C3 cleavage to C3a and C3b. The structure of compstatin consists of a disulfide bridge and a type I ␤-turn located at opposite sides to each other. The disulfide bridge is part of a hydrophobic cluster, and the ␤-turn is part of a polar surface. We present the design of compstatin analogs in which we have introduced a series of perturbations in key structural elements of their parent peptide, compstatin. We have examined the consistency of the structures of the designed analogs compared with compstatin using NMR, and we have used the resulting structural information to make structure-complement inhibitory activity correlations. We propose the following. 1) Even in the absence of the disulfide bridge, a linear analog has a propensity for structure formation consistent with a turn of a 3 10 -helix or a ␤-turn. 2) The type I ␤-turn is a necessary but not a sufficient condition for activity. 3) Our substitutions outside the type I ␤-turn of compstatin have altered the turn population but not the turn structure. 4) Flexibility of the ␤-turn is essential for activity. 5) The type I ␤-turn introduces reversibility and sufficiently separates the two sides of the peptide, whereas the disulfide bridge prevents the termini from drifting apart, thus aiding in the formation of the hydrophobic cluster. 6) The hydrophobic cluster at the linked termini is involved in binding to C3 and activity but alone is not sufficient for activity. 7) ␤-Turn residues 
Compstatin, a 13-residue cyclic peptide, is a novel complement inhibitor with the potential to be developed into a therapeutic agent (1) . Compstatin binds to C3, which is a central complement component, through which all three pathways of complement activation, the classical, alternative, and lectin, converge (2) . Although complement is part of the innate immune system while acting as a bridge between the innate and adaptive immune systems, and its activation is an important line of defense against invading foreign pathogens (3-5), its inappropriate activation can result in host cell damage (6) . This is the case in more than 25 pathological conditions, including a number of autoimmune diseases, burn injuries, ischemia reperfusion injuries, stroke, dialysis, and cardiopulmonary bypass (see Ref. 7 for a complete list and references). The following have been shown. (a) Compstatin inhibits complement activation in vitro in human serum (8) . (b) Compstatin totally inhibits in vivo heparin/protamine-induced complement activation in primates without side effects, in a situation that is typical in cardiac surgery (9) . (c) Compstatin inhibits complement activation without toxicity in whole blood, in models of extracorporeal circuits, which resemble those used in cardiopulmonary bypass, dialysis, and plasmapheresis (10) . (d) Compstatin prolongs the lifetime of porcine-to-human ex vivo perfused kidney xenograft model with human blood (11) . (e) Finally, compstatin does not appear to have significant cytotoxicity as it showed little or no inhibition of clotting (12) .
Compstatin was first identified as a 27-residue peptide using combinatorial phage-displayed random peptide library and was subsequently truncated, without loss of activity, to a 13-residue peptide (8) . An attempt to further truncate the 13-residue peptide yielded inactive fragments (13 12 are disulfidebonded. Reduction and alkylation of the two cysteines result in loss of inhibitory activity (8) . We have determined previously the three-dimensional structure of compstatin in solution using NMR and a restrained hybrid distance geometry/simulated annealing methodology (14) and an alternative refinement methodology using global optimization (15) . Compstatin forms a type I ␤-turn spanning residues Gln 5 -Asp 6 -Trp 7 -Gly 8 . Measurements of inhibitory activities of compstatin analogs designed using an alanine scan in the sequence between residues Cys 2 and Cys 12 have shown that Val 3 and the four residues of the ␤-turn are essential for retaining activity (14) . Alanine replacement for each one of the remaining residues resulted in reduced but not lost inhibitory activity (14) . Fig. 1 , A and C, shows the hydrophobic character of the structure of compstatin. We observe a hydrophobic clustering forming a patch at the linked termini involving residues Ile 1 , Cys 2 , Val 3 , Val 4 , Cys 12 , Thr 13 , whereas the ring of Trp 7 caps the ␤-turn with orientation toward the hydrophobic clustering. We have hypothesized that this hydrophobic clustering may be essential for structural stability and inhibitory activity of compstatin (1, 14) . Fig. 1B shows the electrostatic character of compstatin. Positive charges from His 9 , His 10 (each about 50% protonated at the experimental pH), and Arg 11 and a negative charge from Asp 6 are observed at the opposite side of the hydrophobic cluster. However, a positive charge from the amino terminus is disrupting the hydrophobic cluster. This charge was neutralized by acetylation of the amino terminus in our effort to avoid cleavage of the peptide bond between Ile 1 and Cys 2 during the biotransformation of compstatin (13) . Interestingly, upon acetylation activity of compstatin was increased by a factor of 3 (13) . We then designed our subsequent studies using the more effective sequence of Ac-Ile Because of its activity, low toxicity, and structural simplicity compstatin is a promising candidate for drug development (1, 12, 13) . It is not unusual for a short cyclic peptide to become an oral drug; a successful example is the widely used immunosuppressant cyclosporin (16) . Also, it is known that several immunogenic peptides adopt functional ␤-turn structures (17, 18) . In an earlier study we designed and tested a number deletion analogs of compstatin in an attempt to truncate further the 13-residue peptide, but none of them was active (13) . Neither a retro-inverso analog nor ␤-turn analogs, with substitutions that we expected to enhance a type I or a type II ␤-turn, were active (13) .
With the goal to improve on the activity of compstatin, we have initiated the rational design of compstatin analogs based FIG. 1 . A, the hydrophobic surface of compstatin. Hydrophobic residues are drawn in green, and the rest are drawn in gray. B, the electrostatic surface of compstatin, where blue and red correspond to residues with positive and negative charges, respectively. The orientation is the same as in A. C, a van der Waals sphere representation of compstatin that shows the continuity of the hydrophobic patch in a different view than in A and B. 12 (darker green). Note that this structure corresponds to non-acetylated compstatin at the amino terminus. The lowest energy structure of compstatin has been used from the ensemble of NMR structures deposited in the Protein Data Bank under code 1A1P (14) . The program MOLMOL (29) has been used for molecular representation. Nter, amino terminus; Cter, carboxyl terminus. on the available solution structure and function data. We have constructed 7 analogs by introducing perturbations in the key components of the structure of compstatin, which we have studied using homonuclear two-dimensional NMR spectra. Our goal is to classify which residues are essential for structural stability, activity, or both. Also, we aim to elucidate the roles of the disulfide bridge, of the hydrophobic patch, and of the charges of compstatin in both structural stability and binding/ inhibitory activity. Certain substitutions have resulted in retaining or slightly increasing the inhibitory activity while maintaining the structural stability. Other substitutions have resulted in loss of inhibitory activity while maintaining the characteristic ␤-turn found in compstatin. Finally, some substitutions have resulted in loss of both structural stability and activity. We present here the design of the 7 analogs, one of which is slightly more active than compstatin and one that is equally as active as compstatin.
Despite the presence of multiple conformations (due to flexibility) of small peptides in solution, NMR has been widely used to determine the presence of conformers with distinguishable populations in linear and cyclic peptides, peptide fragments derived from protein sequences, immunogenic peptides, and peptides of de novo design (e.g. see Refs. 17-23, and references therein). These studies typically require the use of two-dimensional correlation spectroscopy (TOCSY, 1 DQF-COSY) for resonance assignments and residue identification and two-dimensional NOE/ROE spectroscopy (NOESY and ROESY) to establish NOE connectivity patterns that are consistent with specific structure (20) . In certain cases, coupling constants, chemical shifts, and temperature coefficients of chemical shifts are also helpful.
Based on the structural data we present here and our earlier experimental work on structure, binding kinetics, and activity, we propose a model for recognition and binding of compstatin to C3.
MATERIALS AND METHODS
Peptide synthesis and purification was performed as described previously (8, 14) . Inhibitory activity of compstatin and its analogs on the complement system was studied by measuring their effect on the alternative pathway. Complement activation inhibition was assessed by measuring the lysis of rabbit erythrocytes in normal human serum, as described previously (8, 14) . All analogs were examined by mass spectroscopy and found to be monomeric. The analogs of compstatin used for NMR studies were acetylated with the exception of the C2A/C12A analog. The NMR samples were prepared in 90% H 2 O, 10% D 2 O buffer containing 50 mM potassium phosphate, 100 mM potassium chloride, 0.1% sodium azide, and 10 M EDTA. Sample pH was ϳ6 for the C2A/C12A, Ac-V3A, Ac-W7F, Ac-Q5G/D6A/W7A, and Ac-Q5G/D6P/ W7F analogs and 6.5 for the Ac-H9A and Ac-V4A/H9A/T13I analogs. Peptide concentrations were in the range of 1.5-5 mM, depending on the analog. NMR spectra were recorded at 5°C.
NMR spectra for the Ac-V3A, Ac-W7F, Ac-H9A, C2A/C12A, Ac-V4A/ H9A/T13I, and Ac-Q5G/D6A/W7A analogs were collected using Bruker DMX 500 MHz spectrometer and for the Ac-Q5G/D6P/W7F were collected using a Bruker AMX 400 MHz spectrometer. DQF-COSY, TOCSY, and NOESY spectra were collected for all analogs using standard pulse sequences (see Ref. 24 and references therein). All spectra were collected using the 3-9-19 pulse sequence with gradients for water suppression (25) . The NOE mixing time was 500 ms and the TOCSY mixing time was 60 ms for the Ac-V3A, Ac-W7F, Ac-H9A, C2A/C12A, Ac-V4A/H9A/T13I, and Ac-Q5G/D6A/W7A analogs. The NOE mixing time was 400 ms, and the TOCSY mixing time was 75 ms for the Ac-Q5G/D6P/W7F analog.
Spectral processing was performed using matNMR, which is a toolbox for processing NMR/EPR data (www.nmr.ethz.ch/matnmr; written by Jacco van Beek) under MATLAB (The Mathworks, Inc., Natick, MA) and for the Ac-Q5G/D6P/W7F analog using Felix (Molecular Simulations Inc., San Diego, CA). In t 2 dimension apodization was performed using Gaussian window functions for the DQF-COSY and NOESY spectra and cosine squared window functions for the TOCSY spectra. In t 1 dimension cosine squared window functions were used for all spectra. The solvent was deconvoluted from the spectra using the time domain convolution method of Marion et al. (26) with a sine bell function. Table I shows the analogs of compstatin we have studied by NMR and their inhibitory activities. These are the single replacement analogs Val 3 3 Ala (Ac-V3A), Trp 7 3 Phe (Ac-W7F), and His 9 3 Ala (Ac-H9A), the double replacement analog Cys 2 3 Ala/Cys 12 3 Ala (C2A/C12A), and the triple replacement analogs Val 4 3 Ala/His 9 3 Ala/Thr 13 3 Ile (Ac-V4A/H9A/ T13I), Gln 5 3 Gly/Asp 6 3 Ala/Trp 7 3 Ala (Ac-Q5G/D6A/W7A), and Gln 5 3 Gly/Asp 6 3 Pro/Trp 7 3 Phe (Ac-Q5G/D6P/W7F). Given that we know the solution structure of compstatin (14) we can now examine by using NMR the following: 1) if the 1 The abbreviations used are: TOCSY, total correlation spectroscopy; DQF-COSY, double quantum filtered correlated spectroscopy; NOE, nuclear Overhauser effect; NOESY, NOE spectroscopy. designed analogs form structures consistent with the type I ␤-turn of compstatin or with some other type of turn or secondary structure; 2) the role of the disulfide bridge in the formation of structure in compstatin; 3) the role of the hydrophobic and polar surfaces in the structural stability of compstatin; and 4) which of the above structural characteristics are essential for function.
RESULTS
We begin our analysis by focusing on the two major types of ␤-turns, type I and II. We test the consistency of the observed NOEs with the expected NOEs for type I and type II ␤-turns. This can be accomplished by examining the following NOEs: (4) NOE is also characteristic of the presence of a ␤-turn of both types, type I and type II. The NOE that distinguishes a type I from a type II ␤-turn is the H N (2)-H N (3), which has strong intensity in the case of a type I ␤-turn and weak intensity in the type II ␤-turn. The turn assignment can be further refined by looking at the intensities of the H ␣ (2)-H N (3) NOE, which should be medium for a type I ␤-turn and strong for type II ␤-turn (20) .
The Linear Analog with Cys 2 3 Ala/Cys 12 3 Ala (C2A/C12A) Double Replacement-In the C2A/C12A analog the two cysteines are replaced by alanines, making it a linear peptide. This is an inactive peptide (Table I ). The rationale for the design of the linear C2A/C12A analog was to test the significance of the disulfide bridge in restricting the conformational space of compstatin and in the formation of the type I ␤-turn. (Fig. 2D ). These two cross-peaks are consistent with the presence of a type I ␤-turn in the segment Gln 5 -Asp 6 -Trp 7 -Gly 8 , as in parent peptide compstatin. Closer examination of the spectra in Fig. 2 (Fig. 2B ), in combination with the H ␣ (i)-H N (i ϩ 2) and H N (i)-H N (i ϩ 1) cross-peaks mentioned above for the fused ␤-turns, is suggestive of the presence of a population forming a turn of a 3 10 -helix (20) in the segment Gln 5 -Asp 6 -Trp 7 -Gly 8 . Based on the observed NOEs for the C2A/C12A analog and the ␤-turn forming analogs (see below), we conclude that the linear sequence of compstatin has a propensity to form a 3 10 helix, which upon formation of the disulfide bond is reduced to a ␤-turn. Interestingly, a type III ␤-turn is classified as a turn of a 3 10 -helix (19, 27 o (which is also the error of calculated dihedral angles from NMR data), the type III ␤-turn is often classified under the type I ␤-turn category. In this report we do not distinguish a type III from a type I ␤-turn. The structure of the C2A/C12A analog is not sufficient for C3 binding and activity (Table I) , which makes the disulfide bridge necessary for activity. Based on the structure of compstatin (Fig. 1) , we propose that the disulfide bridge brings together the termini of compstatin thus contributing to the formation of the hydrophobic patch, which in turn is necessary for recognition and binding to C3.
The Single Replacement His 9 3 Ala (Ac-H9A) Analog-In the Ac-H9A analog the His 9 , right outside the C-terminal residue of the ␤-turn, is replaced by Ala. This is an analog slightly more active than its parent peptide, Ac-compstatin (Table I) . The rationale for the design of the Ac-H9A analog was to introduce additional conformational freedom at one end of the type I ␤-turn by removing the bulky histidine and replacing it with the smaller alanine. This accomplishes a test for the turn stability without losing activity, given that a non-acetylated ring-only form of this analog (with missing residues Ile 1 and Thr 13 outside the peptide ring) was active, although less active than its parent peptide ring-only compstatin ( 4 . NMR spectra of the Ac-V4A/H9A/T13I compstatin analog. Cross-peak labeling is as in Fig. 3. A, portion Fig. 3B ), which is consistent with the presence of a ␤-turn. Fig. 3C (14) , which is absent in the Ac-H9A analog (data not shown). This suggests a slightly increased flexibility or alternatively slightly reduced population of the type I ␤-turn in Ac-H9A analog compared with compstatin.
The above NOE data are consistent with the presence of a weak (with small but observable population) type I ␤-turn in the segment Gln 5 -Asp 6 -Trp 7 -Gly 8 of Ac-H9A analog, as was the case of parent peptide compstatin. In compstatin, the presence of Gly 8 at position 4 of the type I ␤-turn was deemed necessary to reduce side chain steric hindrance for turn reversal. By replacing the next residue His 9 by Ala, we introduced additional flexibility outside one end of the ␤-turn by increasing the available conformational space. This additional flexibility did not alter the type I ␤-turn structure, although it slightly reduced its population. It is worth noting that the population of the type ␤-turn in compstatin was estimated at 42-63% (14) , which suggests flexibility in the parent peptide as well. This analog possesses slightly higher inhibitory activity than compstatin (Table I) , which suggests that flexibility outside the ␤-turn contributes to activity.
The Triple Replacement Val 4 3 Ala/His 9 3 Ala/Thr 13 3 Ile (Ac-V4A/H9A/T13I) Analog-In the Ac-V4A/H9A/T13I analog not only His 9 but also Val 4 , right outside both ends of the ␤-turn, are replaced by alanines, with the rationale of introducing even more conformational freedom outside the turn, than in the Ac-H9A analog. In addition, Thr 13 is replaced with the more hydrophobic isoleucine to enhance the hydrophobic clustering at the termini. This analog is equally active as compstatin (Table I) 11 . Despite the overlaps in individual dimensions, the resulting cross-peaks are distinct (Fig. 4A) . Fig. 4B ). Fig. 4C segment of the Ac-V4A/H9A/T13I analog, which is smaller than the turn population in the same segment of the Ac-H9A analog. Despite the increase of conformational freedom and weakening of the type I ␤-turn, this peptide is an analog equally active to compstatin (Table I) . The fact that both Ac-H9A and Ac-V4A/H9A/T13I but not the linear C2A/C12A analog are active suggests that flexibility between the ␤-turn and disulfide bridge structures is necessary for binding activity.
The Single Replacement Val 3 3 Ala (Ac-V3A) Analog-In the Ac-V3A analog Val 3 is replaced by Ala. The rationale for this replacement was to weaken the hydrophobic clustering at the termini. This replacement resulted in an inactive analog (Table I) . Fig. 5A Based on the NOE data of the Ac-V3A analog, the Val 3 3 Ala replacement has resulted in a stronger (of higher population) type I ␤-turn. It appears that the remote, in relation with the ␤-turn of compstatin, residue Val 3 somehow influences the ␤-turn stability in the parent peptide. Because the activity of the Ac-V3A analog is lost (Table I) , we can say that Val 3 influences the binding of the parent peptide compstatin to C3, possibly either through the hydrophobic clustering of the termini or through some type of stabilization of the ␤-turn. The simultaneous presence of both effects cannot be excluded.
The Single Replacement Trp 7 3 Phe (Ac-W7F) Analog-In the Ac-W7F analog Trp 7 is replaced by Phe. The rationale for this replacement was to enhance the hydrophobicity of the ␤-turn and participation of residue 7 in the hydrophobic clustering, if any (Fig. 1A) . This replacement resulted in an inactive analog (Table I) . Fig. 6A Despite the overlaps in individual dimensions, the resulting crosspeaks are distinct (Fig. 6A) . 6 . NMR spectra of the Ac-W7F compstatin analog. Crosspeak labeling is as in Fig. 3. A, peaks are observed and marked in Fig. 6B. In addition, (Fig. 6C) . Based on the NOE data it appears that Trp 7 specifically is not unique for the formation of the type I ␤-turn, as the turn is present in the Ac-W7F analog as well. The need for participation of an aromatic residue at position 7 in the formation of the type I ␤-turn cannot be excluded. It is also possible that an aromatic residue at position 7 simultaneously influences the structure of the amino-terminal half of compstatin, which is part of the hydrophobic cluster. Because of loss of inhibitory activity in the Ac-W7F analog, it is possible that Trp 7 participates in binding with C3. This could be possible through a hydrogen bond involving the indole amide of Trp 7 as a donor. The Triple Replacement Gln 5 3 Gly/Asp 6 3 Ala/Trp 7 3 Ala (Ac-Q5G/D6A/W7A) Analog-In the Ac-Q5G/D6A/W7A analog Gln 5 is replaced by Gly and Asp 6 and Trp 7 are replaced by Ala. The rationale for this replacement was to introduce steric simplification and flexibility within the ␤-turn of the parent peptide, compstatin. This replacement resulted in an inactive analog (Table I) . (Fig. 7A) . Fig. 7B , we conclude that the Ac-Q5G/D6A/W7A analog is unstructured.
Based on the NOE data, the introduction of flexibility within the type I ␤-turn of compstatin resulted in both loss of the structural stability and loss of inhibitory activity. This suggests that either the type I ␤-turn or specific residues in the turn segment or both are necessary for C3 binding and inhibitory activity.
The Triple Replacement Gln 5 3 Gly/Asp 6 3 Pro/Trp 7 3 Phe (Ac-Q5G/D6P/W7F) Analog-In the Ac-Q5G/D6P/W7F FIG. 7 . NMR spectra of the Ac-Q5G/D6A/W7A compstatin analog. Cross-peak labeling is as in Fig. 3. A, analog Gln 5 is replaced by Gly; Asp 6 is replaced by Pro; and Trp 7 is replaced by Phe. The rationale for this replacement was to enforce the ␤-turn and test relation to activity. We hypothesized that this could be achieved by the following: (a) removal of steric hindrance imposed on the backbone from the side chain of the first residue of the type I ␤-turn by replacing Gln Fig. 8B is a portion of Fig. 8A (Table II) , without performing the NMR analysis, as it was deemed unnecessary. Some of these analogs are active, but only one of them has shown slightly higher activity than Ac-compstatin (Table II) . When comparing the Ac-V3L, Ac-Q5N, and R11K compstatin analogs to compstatin, it appears that Val is slightly preferred than Leu at position 3; Asn is equally preferred as Gln at position 5; and Arg is more preferred than Lys at position 11 (Table II) . Also, the double replacement in the Ac-V3L/Q5N analog resulted in a 2-fold lower activity than Ac-compstatin (Table II) . To address the issue of proteolytic cleavage at Arg 11 during biotransformation of compstatin (13), we have prepared the Ac-R11S, Ac-Q5N/R11A, Ac-H9A/R11A compstatin analogs, none of which was more active than compstatin (Table II) . It appears that Arg is a preferred amino acid at position 11, although the double replacement analog Ac- H9A/R11A showed only about 2-fold reduced activity than compstatin because of compensation from the H9A substitution. Also, replacement of Arg 11 with dArg resulted to total loss of inhibitory activity.
To test further our hypothesis of hydrophobic clustering at the termini, we prepared the Ac-T13I analog, where Thr was replaced with the more hydrophobic Ile to enhance hydrophobicity. This analog showed slightly higher activity than compstatin (Table II) , consistent with our hypothesis. DISCUSSION We have designed seven analogs of compstatin in which we have introduced a series of perturbations in key structural elements of their parent peptide, compstatin. The design was based on the previously determined three-dimensional structure of compstatin (14) . The structure of compstatin consists of a disulfide bridge on one side and a type I ␤-turn on the opposite side. The disulfide bridge is part of a hydrophobic cluster, and the type I ␤-turn is part of a polar surface. The structural perturbations were made to test the effect of specific residue replacements in the structural stability of compstatin and their contributions in binding to C3 and complement inhibitory activity. We know that the disulfide bridge is essential for activity, and we have hypothesized that both the type I ␤-turn and the hydrophobic clustering at the termini are necessary for activity (1, 13, 14) . Our first goal was to correlate structure with activity for each analog and for compstatin. Our second goal was to design analogs that are equally active to or more active than compstatin. Specifically, our structural perturbations were made for the following reasons: 1) to test the significance of the disulfide bridge in the formation of structure in compstatin; 2) to locally alter the structure of compstatin, outside and inside the ␤-turn, to test the structural stability of the ␤-turn; and 3) to locally alter the hydrophobic clustering to test its contribution in the formation of the ␤-turn. The structural analysis of the compstatin analogs was made using NMR data. We used correlation spectroscopy for proton assignments and NOE spectroscopy to elucidate NOE connectivity patterns that are consistent with structure. The known three-dimensional structure of compstatin (14) was used as a base-line structural template for our analysis. Fig. 9 summarizes the backbone NOE connectivity patterns observed for the seven compstatin analogs studied by NMR. The higher intensities of the H ␣ (i)-H N (i ϩ 1) compared with H N (i)-H N (i ϩ 1) NOEs suggest NOE averaging because of the presence of extended conformations, in addition to the observable populations of the proposed structures. This is expected because of flexibility and conformational interconversion that is present in small peptides in solution.
The C2A/C12A linear analog showed a structure consistent with the presence of a turn of a 3 10 -helix. A 3 10 -helix contains a type III ␤-turn, which is typically considered as a special case of a type I ␤-turn, because it differs only by 30 o in 3 and 3 , two of four backbone dihedral angles ( 2 , 2 , 3 , 3 ) used to characterize ␤-turns. This suggests that the sequence of compstatin has inherent propensity to form structures consistent with a turn (helical or reverse). The C2A/C12A analog is inactive which indicates that its structure is not sufficient for inhibitory activity. It appears that the disulfide bridge of compstatin is necessary to bring together the two termini and in effect contribute in the formation of the hydrophobic clustering of residues Ile 1 -Cys 2 -Val 3 -Val 4 -Cys 12 -Thr 13 . Acetylation of compstatin effectively neutralizes the amino terminus, which in charged form (non-acetylated) disrupts the hydrophobic clustering of the termini (the carboxyl terminus is also blocked and neutral). The Ac-compstatin has shown 3-fold increase in inhibitory activity compared with compstatin (12, 13) . This enforces our hypothesis that the hydrophobic clustering of the termini is essential for binding to C3. The remaining six analogs studied here were acetylated.
The fourth residue of the ␤-turn of compstatin, Gly 8 , is a favored residue at position 4 in type I ␤-turns in proteins because the lack of side chain of Gly provides conformation freedom for the formation of the turn. In the Ac-H9A analog we introduced more conformational freedom immediately outside the type I ␤-turn, following Gly 8 , by replacing the bulky His   9 with the simpler Ala. The structure of this analog is consistent with the presence of a type I ␤-turn in the same segment as compstatin but of a slightly reduced population (or in other words a type I ␤-turn with slightly higher flexibility). The population of compstatin itself also suggests flexibility (14) . With a similar rational we prepared the Ac-V4A/H9A/T13I analog where we introduced conformational freedom immediately outside both ends of the type I ␤-turn of compstatin, by simultaneously replacing brunched Val 4 and bulky His 9 with alanines. In addition, we replaced Thr 13 with the more hydrophobic Ile to enhance the hydrophobic clustering at the termini. The structure of this analog is also consistent with the presence of a type I ␤-turn in the same segment as compstatin but of even more reduced population than the Ac-H9A analog. Given that the Ac-H9A analog is slightly more active than Ac-compstatin, the Ac-V4A/H9A/T13I analog is as active as Ac-compstatin, and all three of them incorporate in their structures a 
